News Release - October 9, 2006

Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency

Source: Bristol-Myers Squibb

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.